Neoplasms, Breast research hub

Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

This study looks at a new drug, Niraparib, for certain types of breast cancer: HER2-negative with a faulty BRCA gene or triple-negative breast cancer. It investigates if Niraparib is better than a dummy pill (placebo) after surgery or standard treatment.